Search This Board: 
Created: 08/13/2005 05:47:43 AM - Followers: 101 - Board type: Free - Posts Today: 0

The Big Day is Coming!!!!!!!!!!

 The FDA classified the review of the Complete Response as a Class 2 review and established March 6, 2012 as the target action date under the Prescription Drug User Fee Act (PDUFA) to complete its review and potentially grant marketing approval for SURFAXIN.


Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant therapies to treat respiratory disorders and diseases based on its KL4 surfactant and capillary aerosol-generating technologies. Its development stage products include Surfaxin, a synthetic, peptide-containing surfactant in phase III clinical trial for the prevention of respiratory distress syndrome in premature infants; Surfaxin LS, a Phase III trial product to improve ease of use for healthcare practitioners; and Aerosurf, an aerosolized KL4 surfactant that has completed first pilot Phase II clinical trial for the treatment of respiratory distress syndrome in premature infants.

The company has a license agreement with Philip Morris USA Inc. to use its capillary aerosolization technology for use with pulmonary surfactants for the respiratory diseases and conditions; and a strategic alliance agreement with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain.

Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.


MUST READ!!!!!!!!!!!!!!!!!

  On May 11, 2011, the Company issued a press release highlighting the results of operations for the quarter ended March 31, 2011, and providing an update on its pipeline development as follows:
Surfaxin® (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants: The Company is conducting a comprehensive preclinical program to validate its optimized biological activity test (BAT), a key remaining issue that must be addressed to potentially gain U.S. Food and Drug Administration (FDA) marketing approval for Surfaxin in the United States.  The Company has had several interactions with the FDA intended to ensure that the comprehensive preclinical program would ultimately satisfy the FDA.  In January 2011, the Company announced that the FDA had provided guidance to increase the sample size of a specific data set by testing additional Surfaxin batches.  To comply with the FDA's suggestion, the Company has successfully manufactured eight Surfaxin batches and presently plans to manufacture two additional Surfaxin batches for use in the comprehensive preclinical program. The Company presently plans to complete all related analytical testing and concordance studies, and be in a position to file a Surfaxin Complete Response in the third quarter of 2011.
Surfaxin LSTM (lyophilized lucinactant) for neonatal RDS :  The Company continues to advance this program. Its plans for 2011 include establishing a commercial-scale manufacturing capability at a cGMP-compliant contract manufacturer with expertise in lyophilized formulations and seeking regulatory guidance from the FDA and the European Medicines Agency (EMA) for the planned clinical development program.
Aerosolization Technology :  Recently, at the 2011 Pediatric Academic Societies Annual Meeting (PAS), new data was presented including: (i) a collaborative study indicating that aerosolized KL4 surfactant significantly improved lung function and survival when treating Acute Lung Injury in a well established preclinical model of this severe respiratory condition, (ii) a dose-ranging assessment of aerosolized KL4 surfactant in a widely recognized preclinical model of RDS, demonstrating significant improvement in lung function, lung structural integrity and pulmonary inflammatory mediator profile following treatment with aerosolized KL4 surfactant versus controls, and (iii) a study highlighting the Company's novel patient interface technology intended to increase the efficiency of pulmonary aerosol drug delivery to patients requiring positive pressure ventilatory support.


Regarding the Company's lead aerosolized KL4 surfactant program, Aerosurf® (aerosolized lucinactant for neonatal RDS), data from the preclinical dose ranging assessment study presented at PAS mentioned above suggests that, out of several doses tested, KL4 surfactant delivered via the Company's proprietary capillary aerosol generator during a 20 to 30 minute dosing interval results in the most favorable physiologic outcomes.  This study provides guidance for future clinical dosing strategies for this program. The Company's plans for 2011 include finalizing the clinical and potential commercial design of the capillary aerosol generator, finalizing the clinical and potential commercial design for the novel patient interface, and seeking regulatory guidance in the U.S. and Europe for the planned development program.
For the quarter ending June 30, 2011, the Company projects cash outflow of $5.8 million.



Investor Relations Contacts

John G. Cooper
Executive Vice President, Chief Financial Officer
Discovery Laboratories, Inc.
2600 Kelly Road, Suite 100
Warrington, PA 18976
Tel. 215.488.9490
Fax. 215.488.9391


As of November 8, 2011, 24,499,497 shares of the registrant's common stock, par value $0.001 per share, were outstanding

As of  May 2, 2011, 24,178,502 shares of the registrant's common stock, par value $0.001 per share, were outstanding.  AutAeeeeee

Authorized 50 Mill

85 BM's 5-15-11




2010-11 Press Releases


May 13, 2011 10-Q 

May 13, 2011       A Brighter Decade Ahead for Biotech - Equity Research on Discovery Laboratories and Mylan Inc   

May 11, 2011 8k     

May 19, 2010
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval

May 17, 2010
Discovery Labs' KL4 Surfactant Demonstrates Potential Protective Role for Lung Transplantation in Established Preclinical Model

May 14, 2010
Discovery Labs' Phase 2a Aerosurf® Study Published in Journal of Aerosol Medicine and Pulmonary Drug Delivery

May 5, 2010
Surfaxin LSTM Improves Pulmonary Function and Reduces Lung Inflammation in Established Model of Respiratory Distress Syndrome

April 28, 2010
Discovery Labs' KL4 Surfactant Data to be Presented at Pediatric Academic Societies Annual Meeting and American Thoracic Society International Conference

April 27, 2010
Discovery Labs Provides Updates on Surfaxin®, Other Key Programs and First Quarter 2010 Financial Results

March 10, 2010
Discovery Labs Reports Fourth Quarter 2009 Financial Results and Provides Business Update

February 23, 2010
Discovery Labs Announces Completion of $16.5 Million Public Offering

February 18, 2010
Discovery Labs Prices $16.5 Million Public Offering of Common Stock and Warrants

February 17, 2010
Discovery Labs Announces Proposed Public Offering of Common Stock and Warrants

February 16, 2010
Discovery Labs Receives FDA Guidance Regarding Pathway to Potential SURFAXIN® Approval

January 19, 2010
POPG, a Key Component of Discovery Labs KL4 Surfactant, Identified as a Novel Anti-Viral Therapeutic Approach


Management Team View Bio

W. Thomas Amick, Interim CEO

Russell Clayton, D.O.
Vice President, Academic and Medical Affairs, Acting Head, Regulatory Affairs and Preclinical Research

Kathryn Cole
Senior Vice President, Human Resources

John G. Cooper
Executive Vice President, Chief Financial Officer

David L. Lopez, C.P.A., Esq.
Executive Vice President, General Counsel

Charles F. Katzer
Senior Vice President, Manufacturing Operations

Thomas F. Miller, Ph.D., MBA
Senior Vice President, Commercialization & Corporate Development

Gerald J. Orehostky
Senior Vice President, Quality Operations

Robert Segal, M.D., F.A.C.P.
Senior Vice President, Medical & Scientific Affairs, Chief Medical Officer

Mary B. Templeton, Esq.
Senior Vice President, Deputy General Counsel


Do your own DD & trade smart

(DSCO) Pre-Market Trading     (DSCO) After Hours Trading

(DSCO) Short

Technical Indicators (Barchart) 

Yahoo! Finance (i.e Real-Time)

Last update: June 03,2010

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#3130 G2G 04/20/2022 07:40:17 AM
WINT news coming between now and the next micar 12/13/2021 10:53:40 AM
What happened???????? big bambino 10/19/2021 10:14:08 AM
who revived this taxidermy horse? It wasn't public relations. big bambino 09/29/2021 02:21:36 PM
#3126 Filthy corrupt MM shorts are pulling all their trendzone 08/09/2021 10:14:55 AM
#3125 Thanks. I hope you're right about getting it duderaja 08/09/2021 08:40:23 AM
#3124 It was on Twitter last week, if it trendzone 08/09/2021 08:26:39 AM
#3123 Where did you see that and do you duderaja 08/09/2021 07:27:10 AM
#3122 The reddit crowd must be at it again, trendzone 08/09/2021 07:18:57 AM
#3121 Have any idea what is going on with duderaja 08/09/2021 07:07:16 AM
#3120 Have any idea what is going on with duderaja 08/09/2021 07:06:15 AM
#3119 All the news and the stock sky rockets NYC_JimBob 06/30/2021 02:32:16 PM
#3118 ThurstonHowell 06/29/2021 02:54:36 PM
#3117 ThurstonHowell 06/29/2021 02:51:52 PM
#3116 ThurstonHowell 06/29/2021 02:08:10 PM
#3115 ThurstonHowell 06/29/2021 02:04:55 PM
#3114 Oppenheimer sets target price of $8 per share.... NYC_JimBob 06/17/2021 03:52:12 PM
#3113 ThurstonHowell 06/16/2021 03:28:40 PM
#3112 ThurstonHowell 06/16/2021 03:25:37 PM
#3111 Windtree Therapeutics, Inc. is advancing multiple late-stage interventions ThurstonHowell 06/16/2021 03:23:14 PM
#3109 Yet more news about WINT stock: DueDiligenceMax 06/04/2021 09:30:34 PM
#3108 When 'ClayTrader' says "MONSTER VOLUME" for WINT stock DueDiligenceMax 06/04/2021 05:38:26 PM
#3107 Looking for a (Healthcare) NASDAQ stock whose run DueDiligenceMax 06/04/2021 05:24:51 PM
#3106 * * $WINT Video Chart 06-04-2021 * * ClayTrader 06/04/2021 04:59:42 PM
#3105 MASSIVE VOLUME for a stock at this (NASDAQ) Up/DownTrader 06/04/2021 02:53:49 PM
#3104 WINT's impressive WEBSITE: Up/DownTrader 06/04/2021 01:27:56 PM
#3103 OPPENHEIMER says WINT will outperform via their Covid-19 Up/DownTrader 06/04/2021 11:26:12 AM
#3102 "Benzinga" just upgraded WINT to $8.00 per share! Up/DownTrader 06/04/2021 10:44:07 AM
#3101 WINT is opening-fire!!!! Up/DownTrader 06/04/2021 10:29:16 AM
#3100 BIG NEWS!!! (When you land at the LINK, Up/DownTrader 06/04/2021 10:22:30 AM
#3099 What brought on this volume today? big bambino 06/02/2021 10:04:31 AM
#3098 You’re fine. No need to apologize. Run22222 03/29/2021 12:51:35 PM
#3097 I wasn’t actually intending to buy this stock. PennyStaIker 03/24/2021 11:27:10 AM
#3096 How do you decide whether to put your Ignatz 03/24/2021 11:21:46 AM
#3095 I don’t own this stock lol PennyStaIker 03/24/2021 11:18:38 AM
#3094 If you're not reading the press releases and Ignatz 03/24/2021 10:42:21 AM
#3093 Anyone know why this stock plummeted today? PennyStaIker 03/23/2021 08:37:04 PM
#3092 More breaking news: Windtree Announces FDA Acceptance of big bambino 09/29/2020 10:19:40 AM
#3091 Breaking News: $WINT Windtree to Present at H.C. whytestocks 09/08/2020 04:00:32 PM
#3090 I was actually in this year’s ago when wodehouse 08/21/2020 09:39:42 AM
#3089 I think they finally got back to work big bambino 08/21/2020 09:29:21 AM
#3088 Any idea what happened the end of July Barrydeep 08/20/2020 11:16:00 PM
#3087 9 years with this stock and @ $188 big bambino 08/20/2020 02:42:13 PM
#3086 thanks PennyWorld 06/07/2020 10:07:01 AM
#3085 The FINRA link is only good for the Renee 06/06/2020 06:48:43 PM
#3084 This link is not pulling up anything for PennyWorld 06/06/2020 03:48:06 PM
#3083 WINT moved to the Nasdaq from the OTC: Renee 05/20/2020 08:58:41 AM
#3082 Have not seen any trades in last 2 days? big bambino 04/30/2020 10:01:54 AM
#3081 WINT one for 3 reverse split: (***PPS closed Renee 04/28/2020 04:34:15 PM
#3080 Does anyone know when the next catalyst for big bambino 03/03/2020 09:28:54 AM
Post Subject